
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of potential therapies for oncology, infectious, and autoimmune diseases. With their flagship product, KIMMTRAK, showing strong commercial momentum in the treatment of mUM, the company's valuation is further bolstered by promising late-stage data across its other drug candidates. While there are inherent risks associated with clinical development and commercialization, the company's leadership in the space and proven success in the market make it a strong investment opportunity.
Bears say
Immunocore Holdings is facing challenges as its primary product KIMMTRAK's OS benefit is primarily driven by subsequent therapies, resulting in only 44% of patients being treated with KIMMTRAK alone and 57% of patients discontinuing treatment beyond radiographic progression. Additionally, the company's other drug candidates are still in early stages of development, making it difficult to predict their potential success. The upcoming presentation of five-year OS data at AACR may provide a short-term boost, but the overall outlook for the company remains negative due to these fundamental challenges.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares